## REMARKS

Claims 21-23, 25-28 and 30 remain pending in the application.

Responsive to the preliminary lack of unity determination set forth in the outstanding Official Action, applicants provisionally elect Group A, claims 25-28, directed to the production of a biomolecular complex, with traverse.

The reasons for traverse follow:

PCT Rule 13.2 in Part 1b of the Annex B of the administrative instructions under the PCT specifies that "special technical features" is defined as meaning those features that define the contribution which each of the inventions, considered as a whole, makes over the prior art. Thus, PCT Rule 13.2 requires the citation of a publication showing the "special technical feature".

There is no citation of a publication in the outstanding Official Action, and the publication cited in the Official Action of June 20, 2007 fails to disclose the subject matter of the pending claims.

Therefore, absent any showing that the "special technical feature" shared by the pending claims 21-23, 25-28, and 30 is present in a prior art publication, no determination of lack of unity can properly be made as a matter of law.

Moreover, applicants respectfully submit that there is unity of invention as the biomelecular complex produced in claims

Application No. 10/505,336 Docket No. 1506-1075

25-28 is required for the study of intermolecular interaction as recited in claims 21-23 and 30.

Furthermore, as previously stated in the amendment filed August 20, 2007, the International Searching Authority did not determine the unity of invention as lacking in applying this same legal standard with similar claims. It is still not clear as to why a different legal conclusion was reached with respect to PCT Rule 13.2.

In view of the above, it is believed that the lack of unity determination set forth in the Official Action is improper as a matter of law and should be withdrawn. A favorable action on the merits of all pending claims 21-23, 25-28 and 30, in their full scope, is therefore respectfully requested.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON

Robert Madsen, Reg. No. 58,543

745 South 23<sup>rd</sup> Street Arlington, VA 22202

Telephone (703) 521-2297

Telefax (703) 685-0573

(703) 979-4709

RM/mjr

at in the